TG Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends

Biotech SG&A Expenses: TG vs. Iovance

__timestampIovance Biotherapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014933577224518692
Thursday, January 1, 20151239000019886580
Friday, January 1, 20162560200012631689
Sunday, January 1, 20172126200021977998
Monday, January 1, 20182843000020759000
Tuesday, January 1, 20194084900020838000
Wednesday, January 1, 202060210000121812000
Friday, January 1, 202183664000152137000
Saturday, January 1, 202210409700083231000
Sunday, January 1, 2023106916000122706000
Loading chart...

Infusing magic into the data realm

SG&A Expense Trends: A Tale of Two Biotechs

In the competitive world of biotechnology, managing expenses is crucial for success. Over the past decade, TG Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, TG Therapeutics saw a remarkable increase of approximately 400% in their SG&A expenses, peaking in 2021. This surge reflects their aggressive expansion and investment in administrative capabilities. Meanwhile, Iovance Biotherapeutics experienced a steady rise, with a notable 100% increase from 2018 to 2023, indicating a more measured approach to scaling operations. These trends highlight the strategic differences between the two companies, with TG Therapeutics focusing on rapid growth and Iovance maintaining a steady course. As the biotech industry continues to evolve, understanding these financial strategies provides valuable insights into the future trajectories of these innovative firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025